The clinical trial protocol starts at 0.25 mg to 0.3 mg weekly and increases every 4 weeks through escalation steps of 0.6 mg, 1.2 mg, 1.8 mg, and finally 2.4 mg
The Endocrine Society's framework for off-label peptide prescribing emphasizes that "patient-reported outcomes, captured systematically, are the best available proxy for efficacy in the absence of RCT data." (16) Frequently asked questions How does BPC-157 affect daily life
Discard any vial showing cloudiness, particles, or unusual color
Most are mild and temporary, often related to the injection itself, such as redness, itching, or soreness at the injection site
This article provides a direct comparison between AOD-9604 and tesamorelin